NCT06375187View on ClinicalTrials.gov

Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

May 1, 2027

Conditions
Solid TumorGynecologic CancerBreast CancerGastrointestinal CancerLung Cancer
Interventions
BIOLOGICAL

Engineering Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Juncell Therapeutics

INDUSTRY